Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

PCSK9 Inhibitor Labeling Parity Is Within Reach As Praluent And Repatha Strive To Make Commercial Case

Aug 20 2018

• By Bridget Silverman

Related Content

Praluent Pricing: Collaboration With ICER Sets A New Standard

Mar 12 2018

Ex-US FDA Director John Jenkins Sketches Regulatory Path For Esperion's Bempedoic Acid

Jul 11 2018

<em>Praluent</em> Sponsors Set Tone For PCSK9 Labeling, Post-Marketing Negotiations

Jan 18 2016

Amgen Says Repatha Outcomes Trial Backs Up Its Pricing Math

Mar 20 2017

Outcomes Claim May Help Amgen Make Case For PCSK9 Inhibitor Repatha

Dec 02 2017

Can Cholesterol Drug Sponsors Make The Case For Statin Intolerance?

Apr 21 2017

Amgen's Statin Intolerance Study May Not Cure What Ails PCSK9 Inhibitors

Apr 04 2016

Despite Flat Q2, Sanofi Foresees Growth In H2, Fuelled by IO And Rare Blood Units

Jul 31 2018

Let's Make A Deal: Sanofi/Regeneron Extend A Hand On Praluent, Express Scripts Takes It

May 01 2018

PCSK9 Pick-Me-Up: New Cholesterol Guidelines May Mean Lower LDL Targets

Aug 03 2018

PCSK9 Turning Point? Sanofi/Regeneron Dangle Lower Price Carrot For Praluent

Mar 13 2018

Harper, Hooper Exit As Amgen Revenues Rise

Jul 27 2018

Sanofi/Regeneron's Great ODYSSEY ESCAPE – How Big Is Praluent's Apheresis Benefit?

Aug 30 2016

Related Companies

Sanofi

Regeneron Pharmaceuticals, Inc.

Amgen, Inc.

Esperion Therapeutics, Inc.

Additional Topics

United States Drug Approval Standards Commercial Regulation Cardiovascular BioPharmaceutical

More from Approval Standards

More from Pathways & Standards

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window